Personal history of selected autoimmune disorders and pooled relative risk of major B-cell non-Hodgkin lymphoma (NHL) subtypes or subtype groups*
| Disorder† . | Diffuse large B-cell lymphoma (n = 3709) . | Follicular lymphoma (n = 2712) . | CLL/SLL/PLL/MCL‡ (n = 2096) . | Marginal-zone lymphoma group§ (n = 744) . | ||||
|---|---|---|---|---|---|---|---|---|
| Ever/ never . | OR (95% CI)‖ . | Ever/never . | OR (95% CI)‖ . | Ever/never . | OR (95% CI)‖ . | Ever/never . | OR (95% CI)‖ . | |
| Psoriasis | 70/1974 | 1.11 (0.85-1.46) | 43/1381 | 0.95 (0.68-1.32) | 69/1260 | 1.18 (0.89-1.57) | 10/200 | 1.08 (0.56-2.08) |
| Ulcerative colitis | 38/2664 | 1.23 (0.85-1.78) | 20/2040 | 0.89 (0.55-1.45) | 16/1579 | 1.02 (0.59-1.79) | 6/417 | 1.28 (0.54-3.04) |
| Type 1 diabetes | 7/2875 | 0.59 (0.27-1.31) | 4/1963 | 0.53 (0.19-1.49) | 13/1800 | 1.97 (1.00-3.88) | 2/506 | 1.17 (0.27-5.00) |
| Sarcoidosis | 5/2217 | 0.69 (0.26-1.80) | 4/1810 | 0.63 (0.22-1.82) | 2/1363 | 0.39 (0.09-1.66) | 1/410 | 0.64 (0.08-4.80) |
| Pernicious anemia | 8/1138 | 2.12 (0.87-5.16) | 0/917 | ND | 0/110 | ND | 3/204 | 2.29 (0.58-8.94) |
| Crohn disease | 10/2523 | 1.49 (0.71-3.13) | 1/1970 | 0.16 (0.02-1.23) | 2/1574 | 0.49 (0.11-2.16) | 3/406 | 2.41 (0.69-8.46) |
| Celiac disease | 11/2574 | 1.83 (0.89-3.74) | 6/1795 | 1.13 (0.45-2.85) | 3/1937 | 0.73 (0.21-2.52) | 0/518 | ND |
| Hemolytic anemia | 8/951 | 3.22 (1.31-7.89) | 3/756 | 1.46 (0.40-5.37) | 1/245 | 2.90 (0.31-27.2) | 1/143 | 2.23 (0.24-21.0) |
| Systemic lupus erythematosus | 17/3347 | 2.74 (1.47-5.11) | 9/2455 | 1.70 (0.77-3.74) | 6/2045 | 2.10 (0.825-.42) | 10/583 | 7.52 (3.39-16.7) |
| Multiple sclerosis | 5/2897 | 1.03 (0.38-2.80) | 5/2267 | 1.08 (0.39-2.98) | 2/1483 | 1.07 (0.23-4.96) | 2/603 | 1.37 (0.30-6.20) |
| Sjögren syndrome | 18/2350 | 8.92 (3.83-20.7) | 7/1794 | 3.91 (1.39-11.0) | 1/1397 | 0.62 (0.07-5.07) | 15/396 | 30.6 (12.3-76.1) |
| Primary Sjögren syndrome | 8/2348 | 6.57 (2.12-20.3) | 2/1794 | 1.78 (0.34-9.37) | 1/1397 | 1.01 (0.11-9.15) | 8/396 | 23.1 (7.16-74.6) |
| Secondary Sjögren syndrome | 10/2350 | 12.8 (3.49-47.3) | 5/1794 | 7.55 (1.75-32.7) | 0/1397 | ND | 7/396 | 44.6 (10.6-187) |
| Disorder† . | Diffuse large B-cell lymphoma (n = 3709) . | Follicular lymphoma (n = 2712) . | CLL/SLL/PLL/MCL‡ (n = 2096) . | Marginal-zone lymphoma group§ (n = 744) . | ||||
|---|---|---|---|---|---|---|---|---|
| Ever/ never . | OR (95% CI)‖ . | Ever/never . | OR (95% CI)‖ . | Ever/never . | OR (95% CI)‖ . | Ever/never . | OR (95% CI)‖ . | |
| Psoriasis | 70/1974 | 1.11 (0.85-1.46) | 43/1381 | 0.95 (0.68-1.32) | 69/1260 | 1.18 (0.89-1.57) | 10/200 | 1.08 (0.56-2.08) |
| Ulcerative colitis | 38/2664 | 1.23 (0.85-1.78) | 20/2040 | 0.89 (0.55-1.45) | 16/1579 | 1.02 (0.59-1.79) | 6/417 | 1.28 (0.54-3.04) |
| Type 1 diabetes | 7/2875 | 0.59 (0.27-1.31) | 4/1963 | 0.53 (0.19-1.49) | 13/1800 | 1.97 (1.00-3.88) | 2/506 | 1.17 (0.27-5.00) |
| Sarcoidosis | 5/2217 | 0.69 (0.26-1.80) | 4/1810 | 0.63 (0.22-1.82) | 2/1363 | 0.39 (0.09-1.66) | 1/410 | 0.64 (0.08-4.80) |
| Pernicious anemia | 8/1138 | 2.12 (0.87-5.16) | 0/917 | ND | 0/110 | ND | 3/204 | 2.29 (0.58-8.94) |
| Crohn disease | 10/2523 | 1.49 (0.71-3.13) | 1/1970 | 0.16 (0.02-1.23) | 2/1574 | 0.49 (0.11-2.16) | 3/406 | 2.41 (0.69-8.46) |
| Celiac disease | 11/2574 | 1.83 (0.89-3.74) | 6/1795 | 1.13 (0.45-2.85) | 3/1937 | 0.73 (0.21-2.52) | 0/518 | ND |
| Hemolytic anemia | 8/951 | 3.22 (1.31-7.89) | 3/756 | 1.46 (0.40-5.37) | 1/245 | 2.90 (0.31-27.2) | 1/143 | 2.23 (0.24-21.0) |
| Systemic lupus erythematosus | 17/3347 | 2.74 (1.47-5.11) | 9/2455 | 1.70 (0.77-3.74) | 6/2045 | 2.10 (0.825-.42) | 10/583 | 7.52 (3.39-16.7) |
| Multiple sclerosis | 5/2897 | 1.03 (0.38-2.80) | 5/2267 | 1.08 (0.39-2.98) | 2/1483 | 1.07 (0.23-4.96) | 2/603 | 1.37 (0.30-6.20) |
| Sjögren syndrome | 18/2350 | 8.92 (3.83-20.7) | 7/1794 | 3.91 (1.39-11.0) | 1/1397 | 0.62 (0.07-5.07) | 15/396 | 30.6 (12.3-76.1) |
| Primary Sjögren syndrome | 8/2348 | 6.57 (2.12-20.3) | 2/1794 | 1.78 (0.34-9.37) | 1/1397 | 1.01 (0.11-9.15) | 8/396 | 23.1 (7.16-74.6) |
| Secondary Sjögren syndrome | 10/2350 | 12.8 (3.49-47.3) | 5/1794 | 7.55 (1.75-32.7) | 0/1397 | ND | 7/396 | 44.6 (10.6-187) |
ND indicates not determined.
In analyses of B-cell NHL subtypes, all controls (see Table 5) were used for modeling of risk of diffuse large B-cell lymphoma, follicular lymphoma, and CLL/SLL/PLL/MCL. However, in modeling of risk of the marginal-zone lymphoma group, studies using the older working classification of lymphomas were excluded (Italy, Northern Italy, University of California–San Francisco, representing about 30% of all participants).
Restricted to a history of the autoimmune disorder diagnosed at least 2 years before interview/NHL diagnosis.
Includes patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic leukemia (PLL), and mantle cell lymphoma (MCL) (25).
Includes patients with extranodal (MALT), nodal, splenic, and undetermined marginal-zone lymphoma (25).
Odds ratios (OR) and 95% confidence intervals (CI) computed using a joint-fixed effects model adjusted for age (in 5-year categories), sex, race/ethnicity, education/SES, and study center, with no history of the autoimmune disease in question as reference category.